We hope you’ve been enjoying the preview of CAS life sciences content and capabilities in CAS SciFinder®, which will end on June 1, 2024. These capabilities and many more are now available through the CAS BioFinder Discovery Platform^TM, which includes CAS BioFinder™, our newest solution to serve drug discovery scientists.

The CAS BioFinder Discovery Platform offers seamless integration with the capabilities you’ve seen in CAS SciFinder, such as sequence searches and bioactivity tables linked to reference documents and assay details. In addition, CAS BioFinder features embedded analytical and predictive models to help you explore the predicted behavior of novel molecules. The full platform also includes CAS APIs to directly access our human-curated bioactivity and biomarker data.

With this new platform, you can dive deeper to answer key drug discovery questions with the trusted, harmonized, and connected CAS content you depend on combined with analytical and predictive models directly accessible from your search results.

• What scaffolds and molecules are associated with my disease of interest?
• What molecules are known or likely to interact with my target of interest?
• What targets are known or likely to interact with my molecules of interest?
• What biomarkers are relevant to my disease of interest?